



LKT Laboratories, Inc.

AZD-1152-HQPA

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A9714

CAS No. 722544-51-6

Chemical Name

Synonym AZD1152-HQPA

Formula $C_{26}H_{30}FN_7O_3$

Formula Wt. 507.56

Melting Point


Purity $\geq 98\%$

Solubility DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water Insoluble

Store Temp -20°C

Ship Temp Ambient

Description AZD-1152-HQPA inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for cancers with solid tumors. In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells, AZD-1152-HQPA induces apoptosis, inhibiting proliferation. AZD-1152-HQPA also induces apoptosis in glioma cells, inhibiting proliferation in vitro and tumor growth in vivo.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A9714	1 mg	\$118.40
A9714	5 mg	\$218.70
A9714	10 mg	\$355.30

References Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. *Leukemia*. 2013 Mar;27(3):560-8. PMID: 22940834.

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. *J Neurooncol*. 2012 Jul;108(3):349-60. PMID: 22382783.

Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. *Ann Oncol*. 2011 Feb;22(2):431-7. PMID: 20924078.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.